This site is intended only for healthcare professionals resident in the Republic of Ireland
In PALOMA-2, IBRANCE in combination with letrozole delivered >2 years mPFS in
1st line1,2 with 37.6 months of clinical trial follow-up2
In a 2:1 randomised, double-blind, Phase III trial of post-menopausal women with ER+/HER2- mBC (N=666)1
35.7 months of mPFS with IBRANCE + letrozole (95% CI: 27.7–38.9) vs 19.5 months with placebo + letrozole (95% CI: 16.6–26.6) in a blinded independent central review (HR=0.611; 95% CI: 0.485–0.769)2
Adapted from Finn RS, et al. 20161 and Rugo H, et al. 2019.²
*Evaluated according to RECIST Version 1.1.1 †Data cut-off date: February 26, 2016. ‡Data cut-off date: May 31, 2017.
Updated follow-up of the primary analysis of PALOMA-2: 37.6 months in the IBRANCE + LET arm.2
In an updated non-prespecified subgroup analysis, IBRANCE in combination with letrozole extended mPFS across the 1st line post-menopausal patient subgroups studied vs placebo+ letrozole:²*
*Evaluated according to RECIST Version 1.1.¹
See PALOMA-3 progression-free survival data
Discover how patients responded to IBRANCE combination therapy in the
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023